Garry E. Menzel, President and CEO at TCR2 THERAPEUTICS INC. (TCRR), sold 31,938 shares at $1.06 ($35K) on 2022-12-13, disclosed to the SEC on 2022-12-13.
Scheduled sale ($35k) by President and CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $1.13 | 10,325 | $12K | 33.3% |
| 2 | $1.10 | 10,613 | $12K | 33.4% |
| 3 | $1.06 | 11,000 | $12K | 33.3% |
| Total | $1.10 avg | 31,938 | $35K | 100% |
| Filing → |
| TCRR | SELL | 2022-12-07 | $32K | — | Filing → |
| TCRR | SELL | 2022-12-05 | $12K | — | Filing → |